HC Wainwright Issues Positive Estimate for ALDX Earnings

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Equities research analysts at HC Wainwright increased their Q2 2025 EPS estimates for Aldeyra Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst M. Caufield now expects that the biotechnology company will post earnings of ($0.18) per share for the quarter, up from their prior forecast of ($0.26). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Aldeyra Therapeutics' current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics' Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.54) EPS, FY2026 earnings at ($0.26) EPS, FY2027 earnings at $0.26 EPS and FY2028 earnings at $0.64 EPS.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.08.

A number of other brokerages have also issued reports on ALDX. StockNews.com raised Aldeyra Therapeutics to a "sell" rating in a research note on Wednesday. BTIG Research reduced their target price on Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating on the stock in a research note on Monday, April 7th.

Aldeyra Therapeutics Stock Down 2.5%

Shares of NASDAQ:ALDX opened at $2.36 on Wednesday. The firm has a market capitalization of $141.35 million, a PE ratio of -2.43 and a beta of 0.92. The business has a 50 day simple moving average of $3.38 and a two-hundred day simple moving average of $4.69. Aldeyra Therapeutics has a 1 year low of $1.14 and a 1 year high of $7.20. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80.

Hedge Funds Weigh In On Aldeyra Therapeutics

Several institutional investors have recently made changes to their positions in the company. Hsbc Holdings PLC purchased a new stake in Aldeyra Therapeutics in the fourth quarter worth about $52,000. Balyasny Asset Management L.P. bought a new position in shares of Aldeyra Therapeutics during the fourth quarter valued at approximately $56,000. Capital Advisors Wealth Management LLC bought a new position in shares of Aldeyra Therapeutics during the first quarter valued at approximately $62,000. Wealth Enhancement Advisory Services LLC purchased a new position in Aldeyra Therapeutics during the first quarter valued at approximately $63,000. Finally, Catalyst Funds Management Pty Ltd raised its stake in Aldeyra Therapeutics by 2,083.3% in the fourth quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company's stock worth $65,000 after buying an additional 12,500 shares in the last quarter. Hedge funds and other institutional investors own 59.71% of the company's stock.

Insider Buying and Selling at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the company's stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total value of $4,828,000.00. Following the completion of the sale, the insider now directly owns 5,875,851 shares in the company, valued at approximately $8,343,708.42. This represents a 36.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.60% of the stock is owned by corporate insiders.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.